Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:7 Number:611 ISSN#:2563-5476
ACE Report #5096
Ace Report Cover Tumour

Ewing sarcoma: Similar survival rates with intensified dose regimen of VDC/IE

How to Cite

OrthoEvidence. Ewing sarcoma: Similar survival rates with intensified dose regimen of VDC/IE. ACE Report. 2013;2(7):611. Available from: https://myorthoevidene.com/AceReport/Report/5096

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study

J Clin Oncol. 2009 May 20;27(15):2536-41. doi: 10.1200/JCO.2008.19.1478. Epub 2009 Apr 6

Contributing Authors: L Granowetter R Womer M Devidas M Krailo C Wang M Bernstein N Marina P Leavey M Gebhardt J Healey RC Shamberger A Goorin J Miser J Meyer CA Arndt S Sailer K Marcus E Perlman P Dickman HE Grier

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


478 patients under the age of 30, diagnosed with non-metastatic ESFT (or the Ewing sarcoma family of tumours), were randomized to either a standard or intensified dose regimen of vincristine, doxorubicin, and cyclophosphamide (VDC) along with ifosfamide and etoposide (IE) to assess the 5-year event-free and overall survival rates between groups. Results indicated that there was no significant diff...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.